CAR-T cell therapy in developing countries: how long should we wait?
Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatment...
Saved in:
Main Authors: | Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/12/e009611.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
«Conceptually, we should write not about how we won, but about how we fought on a long journey and through losses came to the Great Victory...»
by: A. A. Zdanovich
Published: (2021-12-01) -
Should We Go Organic?
by: Kate Welch, et al.
Published: (2012-08-01) -
Should We Go Organic?
by: Kate Welch, et al.
Published: (2012-08-01) -
Should we teach physics?
by: Vladimir.B. Yassinskiy
Published: (2022-05-01) -
Where Are We Heading with Noninvasive Clinical Vascular Physiology? Why and How Should We Assess Endothelial Function?
by: Elizabeth A. Ellins, et al.
Published: (2011-01-01)